title: International uniform response criteria for multiple myeloma.
abstract: New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. Categories for stringent complete response and very good partial response are added. The serum free light-chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clarified making confirmation of response and disease progression easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The requirements necessary to use overall survival duration as the ultimate end point are discussed. It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma.
authors.affiliation: Aptium Oncology, Inc., Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA 90048, USA. bdurie@aptiumoncology.com
authors.forename: B G M
authors.initials: BG
authors.lastname: Durie
authors.forename: J-L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: J S
authors.initials: JS
authors.lastname: Miguel
authors.forename: J
authors.initials: J
authors.lastname: Bladé
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
authors.forename: K
authors.initials: K
authors.lastname: Anderson
authors.forename: M
authors.initials: M
authors.lastname: Gertz
authors.forename: M
authors.initials: M
authors.lastname: Dimopoulos
authors.forename: J
authors.initials: J
authors.lastname: Westin
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
authors.forename: H
authors.initials: H
authors.lastname: Ludwig
authors.forename: G
authors.initials: G
authors.lastname: Gahrton
authors.forename: M
authors.initials: M
authors.lastname: Beksac
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.forename: A
authors.initials: A
authors.lastname: Belch
authors.forename: M
authors.initials: M
authors.lastname: Boccadaro
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.forename: I
authors.initials: I
authors.lastname: Turesson
authors.forename: D
authors.initials: D
authors.lastname: Joshua
authors.forename: D
authors.initials: D
authors.lastname: Vesole
authors.forename: R
authors.initials: R
authors.lastname: Kyle
authors.forename: R
authors.initials: R
authors.lastname: Alexanian
authors.forename: G
authors.initials: G
authors.lastname: Tricot
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: G
authors.initials: G
authors.lastname: Merlini
authors.forename: R
authors.initials: R
authors.lastname: Powles
authors.forename: P
authors.initials: P
authors.lastname: Richardson
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: P
authors.initials: P
authors.lastname: Tosi
authors.forename: G
authors.initials: G
authors.lastname: Morgan
authors.forename: S V
authors.initials: SV
authors.lastname: Rajkumar
mesh_terms: D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome